Release Date: September 1, 2008
Expiration Date: December 31, 2009

Target Audience:

This activity is intended for physicians and pharmacists who are interested in the treatment and management of Attention Deficit Hyperactivity Disorder (ADHD).

Goals Statement:

Psychopharmacology expert faculty will review diagnosis and treatment of ADHD. A focus on the disease burden, challenge of current treatments and some emerging treatment options will allow participants to enhance their clinical knowledge. Audience participation will be encouraged by incorporating clinical questions within the presentation especially during the clinical cases.

Psychiatric pharmacy specialists will enhance patient care by translating this information into clinical practice, teaching of psychiatric residents/physicians, and in making more appropriate drug selection decisions for formularies and clinical treatment algorithms.

The College of Psychiatric & Neurologic Pharmacists (CPNP) is the only psychiatric pharmacist professional organization and represents almost 800 specialist pharmacists practicing in the U.S., Canada, and around the world. CPNP's mission is to promote excellence in pharmacy practice, education, and research to optimize the treatment outcomes of individuals affected by psychiatric and neurologic disorders. CPNP has a small physician base to their membership and the organization also markets their educational programs to 800 plus interested physicians in the MidWest U.S. These physicians frequently attend the CPNP meetings and participate in the CE activities due to their recognition of the extensive and state-of-the-art clinical education provided by CPNP especially as it relates to pharmacotherapy.

Educational Objectives:

Upon completion of this activity, participants should be better able to:

• Describe the social and economic impact of ADHD in the United States
• Compare and contrast current pharmacotherapeutic options for ADHD
• Apply guidelines/algorithms to case studies to improve patient outcomes
• Relate new, evolving science and treatment to current guidelines and practice

Accreditation Statements:

Physician Pharmacy Faculty Information and Disclosures:

Julie A. Dopheide, PharmD, BCPP Associate Professor of Clinical Pharmacy Schools of Pharmacy and Medicine University of Southern California Los Angeles, California

Julie Dopheide, PharmD, BCPP has indicated that she is a consultant for Ortho-McNeil-Janssen Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceutical Company, LLC, and Shire Pharmaceuticals.

Steven R. Pliszka, MD Professor and Chief Division of Child & Adolescent Psychiatry University of Texas Health Science Center at San Antonio San Antonio, Texas

Steven Pliszka, MD has indicated that he is a consultant for Shire Pharmaceuticals and receives grant and research support from Eli Lilly and Company and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Instructions:

To receive a statement of credit, you must:

• Review the full content of the activity.
• Successfully complete the post-test (70% or higher).
• You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the posttest and submission of the evaluation form.

Fee:

This activity is complimentary.

Disclosure Declaration:

It is the policy of CEC and CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings.

Approval of credit for this continuing education activity does not imply endorsement by CEC of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Unlabeled Use Disclosure:

This activity includes discussions of products or devices that are not currently FDA approved for the treatment of ADHD, or are currently investigational including alpha agonists (e.g., clonidine, guanfacine), antidepressants (e.g., bupropion, mirtazapine, tricyclics), typical and atypical antipsychotics (e.g., risperidone, aripiprazole, quetiapine, haloperidol, pimozide), lithium, divalproex sodium, melatonin, diphenhydramine, cyproheptadine, dopaminergic antagonists, acetyl-l-carnitine, polyunsaturated fatty acids, FeSo4, and antioxidants.

Supporting Organizations:

This activity is supported by an educational grant from Shire Pharmaceuticals.

Viewing Requirements:

This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.

Please click here for a printable copy of the slides with speaker notes.

Please click here for a printable copy of the slides without speaker notes.

Please click here for a copy of the presentations graphs/charts.

    I confirm that I have read all of the above information regarding this activity.

Please click here to proceed to the activity.